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ABSTRACT  
Background: Many clients who undergo genetic testing (GT) for cancer risk assessment 
receive variant of uncertain significance (VUS) result(s) whose association with cancer is 
unknown and lacks clinical utility. Clients’ cognitive and affective perceptions (i.e. their 
interpretations) of uncertain genetic information often deviate from their memory of the 
information communicated by their genetic health care provider (GHP) (i.e. their 
recollections). This study describes clients’ perceived uncertainties about their VUS 
result and differences between clients’ recollections and interpretations of genetic risk 
information.  
Methods: Participants included adults with one or more VUS result(s) in a cancer 
susceptibility gene identified by GT. Participants completed a survey of quantitative 
scales measuring their perceived uncertainties about their GT result and their 
recollections, thoughts, and feelings about (1) the pathogenicity of their variant result; (2) 
their risk for developing cancer and (3) the likelihood that cancer is hereditable in their  
family. Summary statistics and bivariate analysis were used to describe the outcomes of 
interest.  
Results: Among the 68 participants, the majority were female (93%), Caucasian (97%), 
and college educated (59%). Most participants (82%) had multi-gene panel testing that 
identified one VUS (85%) on average 1.7 years  2.1 prior to study enrollment. 
Participants reported high perceptions of certainty about their GT result with a mean of 
3.97  0.81 out of 5 and a median of 4.06. Although thirty-six participants (60%) recalled 
a VUS result, only 30 (50%) felt their variant was a VUS. Furthermore, many 
participants thought (35%) and felt (43%) differently about their variant’s pathogenicity 
    iii 
than their recollection. Compared to their recollection, participants perceived 
significantly higher cancer risks and hereditary likelihoods (p<0.01). Moreover, most 
participants (≥73.3%) reported that their GT result had influenced their risk perceptions.  
Conclusion: Regardless of their recollection, most participants perceived themselves and 
their families to be at greater risk for cancer suggesting false alarm. It is concerning that 
most clients do not seem to appreciate the inherent uncertainties about their result and 
that they are using their VUS result to inform their cancer risk perceptions. These 
findings have significant implications for what providers should address when conveying 
VUS results.  
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BACKGROUND 
A variant of uncertain significance (VUS) is a genetic mutation whose association 
with disease risk is unknown (National Library of Medicine, 2016). Existing information 
about a VUS result lacks reliability, credibility, or adequacy to classify the sequence 
change either as a normal variation or a disease-causing mutation and is therefore an 
inherently ambiguous test result (Han, Klein & Arora, 2011). The VUS result presents 
challenges to clinicians as they are left to make interpretations and medical management 
recommendations without clear or sufficient information. Currently there are no 
evidence-based guidelines describing how to manage patients who receive a VUS result 
and how or whether these results should be communicated to patients. Due to this lack of 
evidence, the National Clinical Cancer Network (NCCN) guidelines recommend that risk 
evaluation and management of individuals with a VUS in a cancer susceptibility gene 
should rely on empiric evidence based on the individual and family risk factors rather 
than the individual’s genetic status (NCCN, 2016). Individualized management may 
include increased surveillance as well as other interventions, such as surgery or 
chemoprevention based on family history rather than the VUS result.  
Unfortunately, recent research has suggested that clinicians and individuals 
receiving a VUS may over-interpret the meaning of the result and use it to inform 
management (Plon et al., 2011; Vos et al., 2012). It has been argued within the context of 
research that investigators should consider returning a genetic test result when the 
associated risk for disease is high and has significant implications for clinical utility (e.g. 
reproductive implications, preventative screening etc.) (Bookman et al., 2006). However, 
due to its inherent uncertainty the VUS result lacks immediate clinical utility. These 
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challenges have led genetics experts such as Dr. Mary-Claire King, the discoverer of the 
BRCA1 breast and ovarian cancer susceptibility gene, to recommend that genetic 
laboratories refrain from reporting VUS results in the context of population screening for 
BRCA1 and BRCA2. Dr. King maintains, “Our goal is to make the lives of oncologists 
more straightforward, not muddier. That means getting rid of the problem of variants of 
unknown significance, which were invented in the course of commercial activity and 
have run amok since, wreaking havoc for patients and despair for providers who need to 
give patients clear information.” (Helwick, 2015). Still others argue that returning VUS 
results gives patients the opportunity to take part in family segregation studies that can 
aid in reclassifying the variant as a disease causing or benign variation (Garrett et al., 
2016). The potential benefits and harms of disclosing VUS results remain poorly defined, 
and few studies have explored how individuals attribute personal meaning to their result. 
This study explores how individuals who receive a VUS result perceive uncertainty 
related to their result and how this uncertainty relates to their thoughts and feelings about 
the pathogenicity of their result, their personal cancer risks and the hereditary nature of 
cancer in their family. 
Objective and Specific Aims 
The purpose of this study was to describe relationships between the clients’ 
perception of uncertainty related to their variant of uncertain significance (VUS) result 
and their recollection and interpretation of the genetic information communicated by their 
GHP at the time of result disclosure. Informed by Vos’ perception model of genetic 
counseling (2011), outcomes of interest include perceptions of the genetic risk 
information sub-divided into six variables that include recollections and interpretations of 
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(1) the pathogenicity of the VUS result (2) cancer risks and (3) hereditary likelihood. 
Recollections refer to the clients’ memory of the information communicated by the GHP. 
Interpretations refer to the clients’ thoughts and feelings about this information regardless 
of what they recall was communicated by their GHP. Thus, interpretations capture how 
individuals give meaning to the recalled information by selecting, weighing, and 
evaluating the information as a meaning-based approach to coping with the uncertainty. 
First, this study seeks to explore how individuals who receive a VUS result in a 
cancer susceptibility gene perceive uncertainty related to their result. Additionally, this 
study seeks to describe whether discrepancies between client recall and interpretation of 
genetic risk information (including pathogenicity of their variant result, cancer risks, and 
hereditary likelihood) are associated with perceptions of uncertainty related to their VUS 
result. 
Aim 1: To describe how clients who receive a VUS result perceive uncertainty related to 
their result.  
Aim 2: To examine the relationship between perceived uncertainty and interpretations 
among individuals with a VUS result.  
Aim 3: To assess whether perceptions of uncertainty and differences between 
recollections and interpretations are correlated with participant’s personality traits of 
optimism, resilience, intolerance of uncertainty and ambiguity aversion.  
Conceptual Framework 
The conceptual framework (Figure 1) for this study draws from Mishel’s theory 
of perceived uncertainty in illness (1988), Lazarus & Folkman’s transactional model of 
stress and coping (1984), and Vos’s perception model of genetic counseling (Vos et al., 
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2011). Theories and models related to the concepts in this framework will be briefly 
described in this section and then research related to the relationships between these 
concepts will be highlighted in the following sections.  
Figure 1: Proposed Conceptual Framework 
 
The process of making meaning of a stressor or health threat is dynamic and is 
influenced by personal and environmental characteristics as well as the appraisals made 
of the threat (Park and Folkman, 1997). The Transactional Model of Stress and Coping 
(TMSC) posits that when faced with the stress of receiving an uncertain genetic test result 
an individual evaluates the personal significance of what is happening (primary appraisal) 
and what can be done about the result (secondary appraisal). As circumstances and an 
individual’s values, beliefs, and goals (global meaning) change over time so will their 
appraisal, coping, and adaptation to the stressful event. Thus, appraisal and coping are not 
stable states but rather ever changing and influenced by dispositional personality traits as 
well as changes in the health threat and global meanings. Mishel’s Perceived Uncertainty 
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in Illness Theory is like the TMSC in that it theorizes that cognitive appraisals of health 
threats occur prior to coping. According to the theory uncertainty is neither a desired nor 
unwanted state until the implications of uncertainty are determined.  
This study’s conceptual framework is also informed by Vos’ (2011) perception 
model of genetic counseling (refer to page 16 for discussion). Measurement of 
recollections and interpretations of genetic information communicated as part of GCRA 
are key intermediary outcomes because they have been shown to better predict 
psychological, medical, and quality of life outcomes than the objective information 
communicated by genetic counselors (Vos et al., 2012). Outcomes in our model include 
recollections and interpretations of the genetic risk information that have been shown to 
predict downstream behavioral and psychological outcomes not measured in this study.  
Unlike in Vos’ perception model, interpretations in this study include both 
cognitive and affective perceptions of vulnerability when assessing perceived risk. This is 
informed by evidence that risk perceptions themselves can be both cognitive (i.e. thinking 
you are at risk) and affective (i.e. feeling you are at risk). Recent studies among diabetic 
and cancer populations have suggested that affective risk perceptions or affective states 
about risk - such as how worried, anxious or fearful a person is about developing cancer - 
may be better predictors of psychological and behavioral outcomes than traditional 
cognitive perceptions of risk (Portnoy et al., 2013; Janssen et al., 2012). Based on this 
evidence, our model incorporates individual’s cognitive and affective interpretations of 
their genetic risk information separately. 
In our model, the stressor or health threat is defined as receiving a VUS result. 
Informed by Mishel’s theoretical framework, perceived uncertainty is measured as a 
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neutral construct while their appraisal indicates the relevance of the uncertainty to the 
individual. Similar to Mishel’s framework, perception of uncertainties related to the VUS 
result is implicated as a predictor of how individuals will cope with their uncertainty. 
Meaning-based coping in this study is measured by the level at which the individual 
interprets their genetic information as being different than what they recall being 
communicated by their genetic healthcare provider, as informed by Vos’ perception 
model of genetic counseling. Furthermore, based on the TMSC our model proposes that 
this process of making meaning of uncertainty related to a VUS result is influenced by 
the individual’s appraisal of the VUS result and by their dispositional personality traits. 
We plan to assess the influence of these factors via moderation while holding constant 
other environmental characteristics that may influence the coping process.  
Genetic Testing for Cancer Susceptibility Posited 
Although all cancers develop as a result of mutations, only 5-10% of cancers are 
believed to be hereditary in nature (NCCN, 2016). The identification of germline 
pathogenic variants in genes associated with a high probability of cancer such as BRCA1, 
BRCA2, and those associated with Lynch syndrome allows for interventions that can 
significantly reduce the likelihood of developing cancer, make available targeted 
therapies for the treatment of associated cancers, and improve overall survival (Robson et 
al., 2015). These benefits are less understood in more recently described cancer 
predisposition genes that are associated with a moderate to low cancer susceptibility. 
With the tremendous advances in genomic technology the clinical availability of 
genetic tests for hereditary cancer susceptibility is constantly expanding and has pushed 
cancer genetics providers to move beyond a well-established single gene paradigm. A 
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recent study of 603 genetic variants identified through clinical genetic testing for 
inherited cancer susceptibility, showed that a substantial proportion (37%) were classified 
as a VUS. Furthermore, early adopters of multi-gene panel testing for cancer 
susceptibility have shown that a substantial proportion of multi-gene panel tests identify a 
VUS in more than one gene with significant inter-panel variability (Kurian et al., 2014; 
LaDuca et al., 2014). VUS results are more common in a multi-gene panel approach both 
because of the sheer number of genes tested and the limited characterization of some 
genes. Clinically available multi-gene panel tests for hereditary cancer susceptibility 
include anywhere from 5 to 112 genes (GeneTests, 2016) and range between having a 
few high-risk genes focused on a specific organ (e.g. breast or colon) to those including 
all genes associated with tumor development in any organ system. For this reason, the 
probability of receiving a VUS result varies greatly by which test is selected. All existing 
research has exclusively examined how individuals make meaning of a VUS result in 
genes that are related to their personal and/or family history of cancer and in highly 
penetrant genes that if pathogenic would have clear clinical actionability. There is no 
evidence related to how this work may apply to genes conferring a low to moderate risk 
or confer a cancer risk that is discordant with the individual’s personal or family history 
of cancer (Robson et al., 2015).  
Uncertainty 
Uncertainty is a multi-domain construct that is relevant across virtually all aspects 
of health and illness. Although researchers across many disciplines have explored the 
concept of uncertainty, the term has few explicit definitions. Han describes uncertainty as 
the “subjective perception of ignorance” that implies a conscious awareness of one’s lack 
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of knowledge (Han et al., 2011). Babrow et al. (2000) posit that uncertainty arises when 
situations are ambiguous, complex, unpredictable, or probabilistic or when information is 
unavailable or inconsistent. Historically, literature regarding the conceptualization of 
uncertainty had failed to converge around a single model. However, Han and colleagues 
recently proposed an integrative taxonomy that categorizes uncertainty related to its 
sources, issues, and locus (Han et al., 2011). In this model, possible sources of 
uncertainty include probability, ambiguity, and complexity. Probability refers to the 
indeterminacy of future outcomes, ambiguity refers to the lack of reliability, credibility, 
or adequacy of information and complexity refers to the features of information that 
make it difficult to understand such as multiplicity of risks. Although ambiguity is at the 
core of a VUS result, recipients of a VUS may perceive uncertainty from all three 
sources. Under this framework, issues related to uncertainty may be scientific (data-
centered), practical (system-centered), or personal (patient-centered). Finally, the locus of 
uncertainty pertains to whether the uncertainty is experienced by the patient, provider, or 
both. 
Personal uncertainties involve those related to the psychosocial and existential 
issues that are important to the individual, including the personal meaning of illness or 
health information. Personal uncertainties may be strong determinants of reactions and 
behaviors by patients in response to uncertain information. Several qualitative studies 
have described personal uncertainties related to uncertain genetic test results. In one 
recent qualitative analysis of 20 individuals identified to have a VUS in a Lynch 
syndrome gene, participants described personal uncertainties related to whether their 
result meant they had Lynch syndrome, the meaning of the result for their future cancer 
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risks, and their family members’ cancer risks (Solomon, 2013). This study also identified 
affective responses to receiving a VUS result including disappointment, frustration, 
sadness, and relief. These results are similar to another qualitative analysis exploring 
perception of uncertainties related to genome sequencing (Biesecker et al., 2014). In this 
study participants described personal uncertainties regarding how to feel about genetic 
information and whether the results and researchers can be trusted. Responses from this 
study led to the development of a reliable and valid scale aimed at measuring personal 
uncertainties related to genome sequencing in three domains; clinical, affective, and 
evaluative (Biesecker et al., 2016). This study seeks to expand upon this research by 
quantitatively measuring personal uncertainties related to a VUS result and qualitatively 
exploring additional uncertainties that may be unique to individuals receiving a VUS 
result in a cancer susceptibility gene through multi-gene panel testing.  
Personality Traits and Uncertainty 
Research has shown that some individuals interpret uncertain genetic test results 
as threatening information potentially leading to ‘false alarm’, while some interpret these 
kinds of results as an opportunity to believe that they do not carry a genetic 
predisposition for disease, potentially leading to ‘false reassurance’. Studies have not yet 
identified what distinguishes these individuals from each other and the extent to which 
personality traits affect the appraisal and interpretation of medical uncertainty. 
Understanding how personality traits such as intolerance for uncertainty, ambiguity 
aversion, optimism, and resilience contribute to these discrepancies can better inform 
counseling practice by allowing clinicians to tailor interventions aimed at helping clients 
make meaning of uncertain genetic results. 
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Intolerance for Uncertainty 
Research suggests that some individuals have a dispositional tendency toward 
more negative reactions when faced with uncertainty than others that is referred to as 
intolerance of uncertainty (IU) (Carleton et al., 2007). Individuals with relatively higher 
IU have been shown to exhibit a variety of cognitive, emotional, and behavioral reactions 
to uncertain information. For instance, IU has been well established as a key factor in 
predicting worry, and may be a predisposing or exacerbating factor across anxiety and 
major depressive disorders (Einstein, 2014). Furthermore, IU has been demonstrated to 
predispose individuals to approach uncertain situations in an inflexible and negative 
manner (Koerner and Dugas, 2008). 
A small body of research has examined relationships between IU and perceived 
uncertainty related to genetic information. In a recent study of 494 asymptomatic adults 
undergoing genome sequencing, those who perceived high uncertainty were less likely to 
perceive positive health benefits of genome sequencing results only when the individual 
also had high IU (Taber et al., 2015). Additionally, in a study of 64 breast cancer 
survivors who received uncertain genetic results in BRCA1/2, those who had high IU and 
perceived their risk to develop another cancer to be high experienced the highest levels of 
distress a month after disclosure (O’Neill et al., 2006). These results suggest that those 
who are averse to uncertainty may be motivated to interpret the genetic information as 
differing from what was communicated by their genetic provider and to appraise their 
result as more threatening. 
Ambiguity Aversion 
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Ambiguity aversion (AA) is a phenomenon characterized by pessimistic 
appraisals of ambiguous risks and choice options and subsequent avoidance of decision-
making (Ellsberg, 1961). The characteristic that distinguishes AA from IU is that it 
specifically assesses negative reactions to ambiguous information rather than uncertain 
information that can be probabilistic, ambiguous, or complex. A recent survey of 1,074 
adults found that individuals with high AA were more likely to perceive harms related to 
cancer screening and had greater ambivalence about the screening measures (Han et al., 
2014). These results are in line with studies by Taber et al. (2015) that showed that higher 
levels of AA were correlated with lower intentions to learn genome sequencing results 
and Biesecker et al. (2016) that showed those who were more ambiguity averse had lower 
perceptions of uncertainty related to genome sequencing results. Although not directly 
tested in the latter study, authors hypothesized that those who are more ambiguity averse 
may be more motivated to mitigate the threat of uncertainty and thus report lower 
perceptions of uncertainty. Based on this hypothesis those who are ambiguity averse may 
also report lower perceptions of uncertainty related to a VUS result.  
Resilience 
Wagnild (2009) describes characteristics of resilience as perseverance or the act 
of persistence despite adversity or discouragement. Resilience has been found to be 
positively correlated with spiritual growth, health promoting lifestyle practices, and 
psychological wellbeing and negatively correlated with depression and anxiety (Wagnild, 
2009). In a recent survey of 94 parents of children with undiagnosed diseases, resilience 
was associated with lower levels of perceived uncertainty and greater coping efficacy 
(Macnamara, 2014). However, in a study of 551 asymptomatic adults undergoing genome 
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sequencing higher perceptions of uncertainty were correlated with resilience (Biesecker 
et al., 2016). Discrepancy between these findings may at least partially be explained by 
inherent differences in the sources and issues of uncertainty related to raising a child with 
an undiagnosed condition versus related to the potential of future uncertain genetic test 
results. Since we plan to measure perceptions of uncertainty related to VUS results 
utilizing the same scale as the latter study we predict similar positive correlations 
between greater perceived uncertainty and resilience. In this study, we predict individuals 
who are more resilient will be better able to mitigate the threat of uncertainty and more 
apt to acknowledge the uncertainty related to the VUS result in their interpretations. 
Optimism 
Research has found that dispositional optimism, the tendency of an individual to 
expect positive outcomes in life, is protective against poor mental and physical health. 
Furthermore, research in genetic and non-genetic contexts has shown dispositional 
optimism to both directly affect levels of perceived uncertainty and to moderate its 
effects on other outcomes. Among a cohort of parents with children who have 
undiagnosed diseases, those who were more optimistic had lower levels of perceived 
uncertainty and felt more personal control over their child’s condition (Madeo et al., 
2013). Similarly, in a small quantitative study of 30 individuals scheduled to receive an 
implantable defibrillator, those who were more optimistic perceived less uncertainty 
related to the procedure (Carroll and Arthur, 2010). In Taber et al.’s study (2015) those 
with high perceived uncertainty expressed lower intention for learning non-medically 
actionable sequencing results only when they had low optimism. Collectively, these 
studies suggests that those with greater optimism may perceive less uncertainty related to 
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their VUS result and those with low optimism may form more pessimistic appraisals of 
uncertain genetic information. However, optimistic individuals who receive an uncertain 
genetic test result may alternatively be more likely to appraise the uncertainty positively 
and thus more likely to acknowledge the uncertainty related to their VUS result. We 
hypothesize that those with high optimism would be the least likely to over-interpret 
genetic risk information as threatening compared to their recollection of what was 
communicated by their genetic provider because they have an inherit tendency to expect 
positive outcomes. 
Impact of Genetic Uncertainty 
Much of the available research in the realm of genetic testing has suggested that 
receiving an uncertain genetic result is associated with psychological and behavioral 
consequences. Unfortunately, most of the literature on uncertain genetic test results 
resides within the study of Hereditary Breast and Ovarian Cancer (HBOC) associated 
with the BRCA1/2 genes, and for this reason it can be assumed that all studies in this 
section have been conducted in BRCA populations unless otherwise specified. Potential 
uncertain DNA test results include (1) a VUS result and (2) results in which no variant is 
detected in the absence of a known familial mutation referred to as an uninformative 
result (UN). In contrast, certain DNA test results include (1) a pathogenic mutation (PM) 
and (2) results in which no variant is detected in the presence of a known familial 
mutation referred to as true negative (TN). Most studies regarding uncertain genetic 
results have focused on populations receiving UN results, which may not be applicable to 
the experiences of those with a VUS. Based on studies of UN results, many have 
described what Vos refers to as the “genetic uncertainty causes distress hypothesis”, 
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which conjectures that disclosure of uncertain results cause more distress than those with 
certain results (Vos et al., 2008). Some research has provided evidence for this hypothesis 
indicating women who receive a certain TN result had lower levels of distress than 
women receiving an uncertain UN result (van Dijk et al., 2006). However, other studies 
showed reductions in acute distress for those with a VUS result while those with a PM 
result had similar or higher levels of distress (van Dijk et al., 2004). 
Some researchers have also described the effects of uncertain DNA results on 
long-term distress. A retrospective exploratory analysis found that levels of distress and 
anxiety were comparable among individuals receiving uncertain and certain test results 
six months after disclosure and did not reach clinically significant levels (Claes et al., 
2004). O’Neill et al. (2009) found that compared to those receiving an UN result, those 
receiving a VUS had higher genetic test distress one year after disclosure. Furthermore, 
in a retrospective case control study individuals with a VUS reported significantly less 
reduction in cancer distress than those with an UN result (Culver et al., 2013). These 
studies have presented mixed evidence in understanding the relationship between genetic 
uncertainty and psychological distress. One reason for this may be that these studies 
stratified individuals based on their DNA result and not on how they thought and felt 
about uncertainty related to their result. Mishel (1988) posits that anxiety related to 
uncertainty can turn into hope when individuals can reframe their experiences or accept 
the experiences as a natural consequence of life. Therefore, it may be that individuals 
who perceive uncertainty as an opportunity or see positive aspects to receiving a VUS 
result are less likely to experience distress related to the uncertainty. This study seeks to 
explore how individuals with uncertain genetic test results perceive uncertainty related to 
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their result, which could inform future research to better understand the relationship 
between genetic uncertainty and distress. 
The impact of uncertain genetic test results on risk-related behaviors and medical 
management decisions has also been explored. Several studies have reported frequencies 
of prophylactic surgeries after receiving a VUS result that overlap with rates in PM 
cohorts raising concern that patients and providers may be over-attributing meaning to 
the uncertain genetic test result (Vos et al., 2008; Murray et al., 2011). A retrospective 
chart review of 107 VUS carriers found that 13 of 22 individuals who had risk-reducing 
oophorectomy reported that uncertainty related to their genetic test result influenced their 
decision (Murray et al., 2011). Similarly, a prospective study of 183 women with an 
uncertain UN result showed similar intentions for mammogram screening as those who 
received a certain PM result (van Dijk et al., 2005). These studies suggest clients’ 
reactions to uncertainty related to their genetic result influence how they make decisions 
about their future medical management. Understanding how clients perceive uncertainties 
related to their result and how these perceptions influence their interpretations of genetic 
information could have important implications for how we communicate uncertainty and 
evaluate medical options with clients in the posttest counseling discussion. 
Another commonly investigated outcome among individuals with uncertain 
genetic results is risk perception. Several studies have identified that a subset of 
individuals receiving uncertain UN results perceive their result as a certain TN, a 
phenomenon described as “false reassurance” (Bish et al., 2002; Claes et al., 2004). 
However, studies investigating those with an uncertain VUS show a greater variety in 
interpretation with some perceiving the result as a certain TN and some as a certain PM 
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(Ritcher et al., 2013;Vos et al., 2008). In studies specific to those with VUS results, risk 
perception has typically been operationalized as perception of cancer risk. A study of 36 
VUS carriers found that 93% of participants perceived a change in their risk for cancer 
after disclosure of the VUS result, of which 32% of these perceived their risk for breast 
cancer as higher post disclosure (Ritcher et al., 2013). However, van Dijk et al (2004) 
found that perceptions of breast cancer risk did not change significantly post-disclosure 
among VUS carriers (van Dijk et al., 2004). Some studies seem to suggest that 
individuals have inaccurate perceptions of the meaning and significance of their uncertain 
DNA result on their health despite studies reporting high levels of comprehension of 
these results post-disclosure (van Dijk et al., 2004). Inconsistencies may be due to 
challenges with operationalization, as some individuals may be reporting on their 
recollection of what risk information was communicated while others are reporting on 
their own subjective meanings. Studies that have made this distinction between recall and 
interpretations of risk perception are discussed in the following section. 
Differences in Recollection and Interpretation of Uncertain Genetic Information 
Many individuals receiving uncertain DNA results differentiate between their 
recollection and interpretation of genetic information communicated by their genetic 
healthcare provider (Vos et al., 2008; Cypowyj et al., 2009; Solomon, 2013). In an 
exploratory qualitative study of 24 women with a VUS in BRCA1/2 genes, most women 
in the study had a different interpretation than their recollection with 79% interpreting 
their VUS result as a PM and 21% as a TN (Vos et al., 2008). The authors proposed that 
when faced with uncertain genetic results individuals interpret the result with greater 
certainty as an adaptive way of coping with uncertain information (i.e. as a form of 
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meaning based coping). Given this hypothesis, perceptions of uncertainty and appraisals 
may influence a client’s reinterpretation of genetic information communicated by their 
genetic healthcare provider. However, research has not explored how perception of 
personal uncertainties related to VUS results influence differences between recollection 
and interpretation of genetic information. 
Responses from this qualitative study led to the development of a valid and 
reliable scale aimed at assessing an individual’s recollections and interpretations of both 
their cancer-risks and hereditary-likelihood (Vos et al., 2011). This scale was utilized in a 
retrospective study of 206 patients who had undergone BRCA testing in which 76 
received a VUS result, 77 an UN result, and 53 a PM result. In this study the authors 
collected information from patient visit summary letters to compare communicated 
genetic information to the individuals’ recollections and interpretations. This study found 
that differences in recollections and interpretations of cancer risks and hereditary 
likelihood were greatest among those receiving a VUS result. Furthermore, the majority 
with a VUS overestimated their cancer risks and hereditary likelihood when compared to 
what their genetic counselor had communicated. This study supports the hypothesis that 
clients reinterpret genetic information as a form of meaning based coping. Furthermore, 
the observation that greater differences between recollection and interpretations were 
observed in the VUS group may be explained in part by the uncertainty related to the 
result and warrants further investigation. 
Vos and colleagues went on to show that among the 76 participants in the VUS 
group, psychological outcomes, quality of life, BRCA-related stigma and vulnerability 
and medical outcomes were better predicted by the participants’ interpreted cancer risks 
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and hereditary likelihoods than by the communicated information (Vos et al., 2012). 
These findings were confirmed in a small prospective study of 16 VUS carriers surveyed 
pretest and three months post-disclosure (Vos et al., 2012). In both studies, those who 
interpreted their risks as greater than what was communicated by their genetic healthcare 
provider had more worries, distress, and greater uptake in prophylactic surgeries. 
Collectively these findings support the experience of false alarm and suggest that 
individuals receiving a VUS may appraise the result as a danger leading to over-
estimation of cancer risks and hereditary likelihood and radical management. 
This body of research advances our understanding of how individuals react and make 
personal meaning of uncertain genetic results in HBOC genes. However, several 
limitations to the generalizability of these results exist. First, these results may not reflect 
how individuals recall and interpret uncertain results in other cancer predisposition 
syndromes. Second, participants in the reviewed research have a personal and/or family 
history of cancer that is concordant with the genes tested. However, in the reality of 
multi-gene panel testing, patients often receive testing for genes that are not concordant 
with their specific personal and family phenotype. It is unclear in these cases whether 
individuals will perceive cancer risks and hereditary likelihood as related to the types of 
cancers in their personal/family history or the types of cancers associated with the gene 
their VUS was identified in.  
METHODS 
Study Population  
Men and women who had genetic testing that identified one or more VUS 
result(s) in a cancer susceptibility gene no less than one month prior to the time of 
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recruitment were eligible for the study. Individuals had to be enrolled in an inherited 
cancer registry in which they have given permission to be contacted for future research. 
Exclusion criteria included individuals who are less than 18 years old, are not able to read 
and write in English, have a known variant in a cancer susceptibility gene classified as 
pathogenic, polymorphism, likely benign, or benign and whose VUS result(s) had been 
reclassified. The sample size calculation indicated that 240 participants were needed to 
have 80% power to detect the effect of a key independent variable to explain a small-to-
medium effect size of at least 3.3% of total variance in differences in interpretation. 
Recruitment Strategies 
Participants were recruited through pre-existing research registries at two NCI 
designated comprehensive cancer centers; Moffitt Cancer Center located in Tampa, FL 
and City of Hope located in Duarte, CA. Participants are largely recruited to the registry 
through high-risk genetics clinic. As part of registry enrollment participants agree to be 
contacted in the event of future research opportunities. The registry research coordinators 
extracted eligible cases according to the inclusion/exclusion criteria and assigned each 
case a unique password to be used as the identifier for this study. The research 
coordinators emailed the eligible potential participants the recruitment letter (Appendix 
A), which included their unique password and a link to the informed consent document 
(Appendix B) and survey (Appendix C). Potential participants who did not have an email 
address were mailed the recruitment letter.  
Procedures 
This study involved a one-time self-administered survey. Individuals interested in 
the study were instructed to either access the web-based survey through a secure website, 
    20
SurveyMonkey, or to contact the researcher for a paper version of the consent document 
and survey. The first page of the online survey included a link to the consent document.  
Potential participants had the opportunity to read the recruitment letter and consent 
document at their leisure from the privacy of their homes and decide whether to 
participate. Participants were instructed that they could withdraw from the study and 
could discontinue the survey at any time. Participants were not asked to provide any 
identifiable information on the survey.  
If cancer registrants were interested in participating they completed three 
screening questions, checked a box and inputted their unique password indicating that 
they had read the consent document and voluntarily agreed to participate. If the potential 
participant did not agree with any of the three screening questions they were thanked for 
their interest and instructed to exit the survey. Potential participants could decline the 
survey by checking a box and inputting their unique password on the first page of the 
web survey. A second recruitment email/mailing was sent by the registry research 
coordinator to all potential participants who had not completed, been deemed ineligible 
or declined the survey within 3 weeks of the first contact. Upon closure of the survey, the 
registry research coordinator released select genetic test report and clinical information 
for those participants who completed the survey linked to their unique passwords. Survey 
responses were collected from August 28, 2016 through January 5, 2017. This study was 
approved by the Institutional Review Boards of the University of South Florida (Protocol 
number Pro00026887) and City of Hope Hospital (Protocol number# 16219). The study 
was determined to be exempt from NHGRI IRB approval by the NIH Office of Research 
Protections (#13319).  
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Study Design 
This study used a cross-sectional survey research design. Validated instruments 
were used to assess perceived uncertainties related to their VUS result, intolerance for 
uncertainty, ambiguity aversion, resilience, and optimism. The scales used to measure 
recall and interpretations of the VUS pathogenicity, cancer risks, and cancer heritability 
were adapted from Vos’ validated scales (Vos et al. 2012). The survey was piloted among 
collaborating researchers, genetics experts and laypersons. The survey took 
approximately 15-20 minutes to complete.  
Study Instrument 
The survey (Appendix C) included scales to measure (1) personal uncertainties 
related to their genetic test result; (2) recollections and interpretations of the variant 
pathogenicity, cancer risks, and hereditary likelihood; (3) the degree to which their 
genetic test result influenced their interpretations; (4) personality traits and (5) decisional 
regret.  
The Perceptions of Uncertainties in Genome Sequencing (PUGS) Scale 
The PUGS scale was used to measure participants’ perceptions of certainty or 
uncertainty about their genetic test result. The PUGS was developed to assess anticipated 
personal uncertainties related to genome sequencing as informed by Han’s conceptual 
taxonomy of uncertainty in health care (Han et al., 2011). The PUGS is an 8-item scale 
encompassing three domains; clinical (three items), affective (three items), and evaluative 
(2 items). An example of items in each domain are “what actions I need to take based on 
my test results” in clinical, “whether to be worried or concerned about my test results” in 
affective, and “whether my test results are accurate” in evaluative. For each item 
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participants rated their level of certainty or uncertainty regarding their genetic test result 
on a 5-point Likert scale from 1 (very uncertain) to 5 (very certain). Final summed and 
averaged uncertainty scores can range from 1-5 with higher scores indicating greater 
certainty. Preliminary psychometric evaluation of the PUGS scale has found it to be valid 
and reliable (Cronbach’s α = 0.83; Biesecker et al., 2016). An open-ended question was 
used to capture any additional ways that participants felt certain and/or uncertain about 
their genetic test result that were not captured by the PUGS scale. 
To assess what Han and colleagues (2011) describe as the locus of uncertainty 
(i.e. whether uncertainty is experienced by the patient, provider, or both) participants 
completed the 5 items in the clinical and evaluative domains of the PUGS scale a second 
time rating their genetic counselor and/or physicians’ level of certainty or uncertainty 
about their genetic test result. To adapt the scale for this purpose the heading was 
modified in a way that prompted participants to rate their genetic providers’ level of 
uncertainty and the item “how my doctor may use my results to improve my health” was 
modified to “how they may use my results to improve my heath” as well as the item 
“whether I can trust my test results” was modified to “whether they can trust my test 
results”. The additional items and scoring of the scale remained the same.  
Recollections and Interpretations of Pathogenicity, Cancer Risks, and Hereditary 
Likelihood 
The items used to measure recollections and interpretations were adapted from 
Vos et al. 2008 & Vos et al. 2012. Participants first answered three items regarding their 
recollection of what their genetic healthcare provider had communicated, regardless of 
their thoughts and feelings; (1) the classification of their genetic test result, (2) the chance 
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that they will develop cancer in the future, and (3) the chance that cancer is hereditary in 
their family. Subsequently, in the interpretation section of the survey participants 
answered the same three questions under the instruction that they describe their own 
thoughts and feelings regardless of what their genetic healthcare provider had 
communicated. 
DNA Result Pathogenicity 
Participants were first prompted to “think about the one variant that is most 
important or that you feel may mean the most for you” and then were asked to report how 
their genetic counselor or doctor had classified that variant by selecting 1 of the 5 
standardized classification categories put forth by the American College of Medical 
Genetics (2015): benign, likely benign, uncertain significance, likely pathogenic, and 
pathogenic. A description of “benign”, “uncertain significance”, and “pathogenic” were 
provided. Subsequently, participants were prompted to think about the same variant and 
to complete the sentences “I think my variant is…” and “I feel my variant is…”  using the 
same 5 classification categories.  
General Cancer Risk Perception 
Participants first rated their risk to develop cancer in the future according to their 
genetic counselor or doctor on a 7-point scale from 1 (extremely unlikely) to 7 (extremely 
likely). In the subsequent section they were asked to complete the sentences “I think my 
risk to develop cancer in the future is…” and “I feel my risk to develop cancer in the 
future is…” using the same 7-point scale. Two open-ended questions were used to 
capture what types of cancer participants thought and felt they were at risk of developing 
respectively.  Finally, participants rated in two items how much their genetic test result 
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had influenced their thoughts and feelings about their risk to develop cancer in the future 
on a 7-point scale from 1 (not at all) to 7 (extremely). An open-ended question was used 
to collect the specific ways (if any) that their genetic test result had changed their cancer 
risk perceptions.  
Hereditary Likelihood 
Participants first rated the chance that cancer is passed down from generation to 
generation in their family according to their genetic counselor or doctor on a 7-point scale 
from 1 (extremely unlikely) to 7 (extremely likely). In the subsequent section, 
participants were asked to complete the sentences “I think the chance that cancer is 
passed down from generation to generation in my family is…” and “I feel the chance that 
cancer is passed down from generation to generation in my family is…” using the same 
7-point scale. Two open-ended questions were used to capture what types of cancer 
participants thought and felt were passed down in their family from generation to 
generation respectively.  Finally, participants rated in 2 items how much their genetic test 
result had influenced their thoughts and feelings about their risk to develop cancer in the 
future on a 7-point scale from 1 (not at all) to 7 (extremely). An open-ended question was 
used to collect the specific ways (if any) that their genetic test result had changed their 
perception of hereditary likelihood of cancer in their family. 
Intolerance of uncertainty 
General intolerance for uncertainty was measured using the 7-item Intolerance of 
Uncertainty Scale (Carleton, Norton, Asmundson, 2007; α= 0.80), which assesses the 
extent to which individuals are comfortable with uncertain situations. Participants are 
asked to indicate how characteristic each of the 7 statements are for them on a 5-point 
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scale ranging from 1 (not at all characteristic of me) to 5 (entirely characteristic of me). 
Final summed and averaged scores can range from 1-5 with lower scores indicating a 
greater intolerance for uncertainty.  
Dispositional optimism  
Dispositional optimism was measured using the average of the sum of 3 items (1, 
4, & 10) from the Life Orientation Test-Revised (LOT-R) scale (Scheier et al., 1994; α= 
0.85). Items are scored on a 5-point scale ranging from 1 (strongly disagree) to 5 
(strongly agree). Final summed and averaged scores can range from 1-5 with higher 
scores representing higher optimism.  
Ambiguity aversion  
Medical ambiguity aversion was measured using the 6-item Ambiguity Aversion 
in Medicine scale (AA-Med), which assesses an individual’s aversion to medical tests or 
treatments that experts have conflicting opinions about (Han et al., 2009; α= 0.79). Items 
are scored on a 5-point scale ranging from 1 (strongly disagree) to 5 (strongly agree). 
Two items (4 & 5) are reverse scored and all 6 are summed and averaged. Higher scores 
indicate greater ambiguity aversion. 
Resilience  
Resilience was measured using the 10-item Connor-Davidson-Resilience Scale 
(CD-RISC) that assesses an individual’s perceptions about their ability to recover from or 
adapt positively to difficult situations (Campbell-Sills & Stein 2007; α= 0.85). Items are 
scored on a 5-point scale ranging from 0 (never true) to 4 (always true). A total resilience 
score is calculated by summing the responses, and higher scores indicate higher 
resilience. 
    26
Decision Regret 
The Decision Regret Scale was used to measure the extent to which participants 
regretted having had genetic testing. The Decision Regret Scale was developed to 
measure “distress or remorse after a (health care) decision” (Brehaut et al. 2003; α= 
0.81). Respondents were asked to reflect on their decision to have genetic testing, and 
then asked to indicate the extent to which they agree or disagree with 5 items on a 5-point 
scale ranging from 1 (strongly agree) to 5 (strongly disagree). Two items are reverse 
scored (2 & 5) and all 5 are summed and averaged. Higher scores indicate greater regret.  
Other covariates 
Additional questions were included to account for other possible confounding 
variables associated with perception of uncertainties, recall and interpretations of DNA 
result pathogenicity, cancer risks, and hereditary likelihood. These include four yes or no 
questions assessing (1) whether the participant is the first person in their family to have 
genetic testing (2) whether they were aware of the possibility of uncertain test results 
prior to disclosure (3) whether they received a genetic counseling summary letter or test 
report and (4) whether they reviewed their letter or test report during the survey. Finally, 
to assess subjective comprehension respondents were asked to rate how well they feel 
that they understand their genetic test result on a 5-point scale ranging from 1 (not at all) 
to 5 (very good). 
Registry Data 
Select clinical and test report data was obtained from the research registry. Data 
provided by the research registry included: (1) self-reported cancer-related personal and 
family health information (i.e. types of cancers, ages at diagnosis, and relationship to the 
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participant); (2) self-reported demographics (i.e. gender, race/ethnicity, highest level of 
education, marital status, number of children, and sex of their children); and (3) 
information from the genetic test report (i.e. date of the test, whether the genetic test 
ordered was for a single gene or multi-gene panel and the name of the gene(s) in which a 
VUS was identified). The data obtained from the registry originated through prior self-
reported questionnaires, a pedigree collected by a genetics health care provider, and the 
clinical genetic test report.  
RESULTS 
Recruitment 
A total of 514 individuals were deemed eligible by the research coordinators at 
each participating institution and were approached for recruitment. There were 204 
eligible participants at Moffitt Cancer Center and 310 eligible participants at City of 
Hope. The majority of participants were emailed the recruitment letter (81% of eligible 
cases at Moffitt and 59% of eligible cases at City of Hope). During the recruitment period 
from August 26, 2016 to January 5, 2017, 79 individuals started the online survey. No 
individuals declined the survey or were determined ineligible by the eligibility screening 
questions at the beginning of the survey. However, over the course of recruitment seven 
potential participants were deemed ineligible to participate by the registry and 12 
potential participants were unable to be reached due to inaccurate contact information.  
The overall response rate was 16% (79/495). 
All participants answered the survey electronically. Approximately 18% (n=14) of 
surveys were incomplete. In the majority of the incomplete surveys, participants did not 
answer beyond inputting their unique passwords, answering the eligibility questions, and 
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agreeing to participate. This suggests that these individuals likely felt that they were 
ineligible to participate after reading the criteria. Sixty-eight individuals (86% of 
respondents) completed at least some of the survey items. Participants were able to skip 
any question(s), therefore, the sample sizes for the scales vary, depending on each scales’ 
missing values.  
Table 1. Participant Recruitment (n=68) 
Recruitment Source N (%) Response Rate 
Moffitt Cancer Center 34 (50%) 16.7% 
City of Hope 34 (50%) 11.7% 
 
Patient Characteristics and Demographics  
The mean age of participants in the study was 55.4 years ( 12.3). Participants 
were primarily female (93%), Caucasian (88%), married (71%), and college educated 
(59%). The majority of participants (82%) had a personal history of cancer of which the 
most common type was breast cancer (57%). All but two participants (97%) had a family 
history of cancer of which the most common type was breast cancer (66%). Table 2 
summarizes the characteristics of the sample. Time since having genetic testing ranged 
between 4 months to 13 years with a mean time of 1.7 years  2.1.  Most participants had 
multi-gene panel testing (84%) that identified one VUS in a cancer susceptibility gene 
(82%). Seventy-nine VUS results were identified in 26 genes among the sample. The 
most common gene reported to have a VUS was BRCA2 (16%). The types of cancers 
associated with each gene were determined by reviewing National Comprehensive 
Cancer Network Guidelines and those reported in the clinical synopsis of the Online 
Mendelian Inheritance in Man (OMIM) catalog (Appendix D). These gene-cancer 
associations were used to determine which individuals had a VUS result in a gene that 
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was associated with their personal and/or family history of cancer. The names and 
frequency of genes harboring a VUS are described in Figure 2. 
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Figure 2. Frequency of genes with a VUS (n=79) 
 
 
* VUS genes that were present once in the sample population: DIS3L2, MSH6, MUTYH, POLD1, 
RAD51D, SDHC, SMAD4, STK11, TSC2, VHL 
Data Analysis 
Data were analyzed using the Statistical Package for the Social Sciences (SPSS) 
version 24.0 software. Frequencies were calculated for categorical variables and 
descriptive statistics including means, medians, ranges, and standard deviations were 
calculated for continuous variables. Associations between key variables were determined 
by t-tests and correlations. Bivariate analysis was used to explore the relationships 
between uncertainty and differences between recollections and cognitive and affective 
interpretations. Any analysis that resulted in a p-value ≤ 0.05 was considered statistically 
significant. Content analysis was conducted for open ended responses using the 
taxonomy of medical uncertainties in clinical genome sequencing (Han et al., 2017). 
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Perceptions of Uncertainties in Genome Sequencing (PUGS) Scale 
The Personal Uncertainties in Genome Sequencing Scale (PUGS) was used to 
assess the participant’s perceptions of uncertainty related to their genetic test result. 
Higher mean scores indicated greater certainty (possible range is 1-5). Overall, 
participants reported high levels of certainty about their genetic test result with a mean of 
3.97 and a SD of 0.81. Scores ranged from 2.13 to 5 and the median was 4.06. The 
skewed distribution (Figure 3) suggests that the majority of participants perceive greater 
certainty than uncertainty about their VUS result.  Descriptive statistics for the PUGS’ 
three subscales are individually reported in the following sections. 
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Clinical Uncertainty 
Uncertainty about the genetic test result’s clinical utility was assessed with 3 
items which asked about uncertainty related to how their result may affect their health, 
what actions they should take based on their result, and how their doctor will use their 
result to improve their health. Participant’s clinical uncertainty scores ranged from 1 to 5, 
and the mean was 3.92  1.06.  
Affective Uncertainty 
Affective uncertainty was assessed by three items which asked participants about 
uncertainty in whether they should be worried and concerned, alarmed, or if their results 
will disrupt their life. The scores for affective uncertainty ranged from 1 to 5, and the 
mean was 3.80  1.12.  
Evaluative Uncertainty 
Uncertainty about the accuracy and trustworthiness of the genetic test result was 
assessed with 2 items. Participant’s evaluative uncertainty scores ranged from 1.5 to 5, 
and the mean was 4.30  0.81.  
Additional Uncertainties 
Participants were asked in an open-ended question to list any additional 
uncertainties they had that were not captured by the PUGS. As expected among a 
population of individuals who reported relatively high certainty on the PUGS, most 
participants (70.6%) either left the question blank or reported no additional uncertainties. 
Of those 20 who did report additional uncertainties, 3 participants simply mentioned that 
they had a variant of uncertain significance. The additional 17 responses were coded 
using Han and colleagues’ taxonomy of medical uncertainties in clinical genome 
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sequencing. Guided by the taxonomy, participants conceptualized their additional 
uncertainties within two categories; ambiguity and scientific issues of uncertainty. Ten 
participants spoke to the ambiguity of their test result, with the majority (8/10) expressing 
uncertainty about whether there are genetic risk factors that were not identified by their 
testing and when they should have updated testing/information. Two participants 
mentioned uncertainty about conflicting interpretations of their genetic test result; in one 
case by two genetic laboratories and in another by two different health care providers. 
Eight participants spoke to the prognostic, diagnostic, and therapeutic uncertainties they 
had given their variant of uncertain significance result. Half (4/8) expressed uncertainty 
related to the implications of the result for family members and themselves. Another 
three participants spoke to uncertainty about their variant’s association to cancer risk and 
one participant queried about whether there were treatments for her specific variant.  











 Test misinterpretation 
(n=2) 
 
“I am unsure if I have other abnormalities that may later 
be found to put me a greater risk.” (Pt. 45) 
 
“How often I need to have new tests.” (Pt. 64) 
 
“One test was of undetermined significance and my 
genetic doctor was not concerned about it. But later other 
doctors have attached meaning to it related to my cancer 
history.” (Pt. 12) 
Scientific 
 Prognostic (n=4) 
 
 Diagnostic (n=3) 
 
 Therapeutic (n=1) 
 
“Whether the results have any implications for my 
children.” (Pt. 54) 
 
“With a variant of unknown significance I am unsure if I 
have a higher risk for cancer that is genetic.” (Pt. 45) 
 
“Any treatment for my specific gene mutation.” (Pt. 58) 
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Personality Traits 
Intolerance of Uncertainty  
Participant’s intolerance for uncertainty was measured using an abbreviated version of 
the Intolerance in Uncertainty Scale. Lower scores indicate individuals with greater 
intolerance for uncertainty (possible range is 1-5). Intolerance of uncertainty scores 
ranged from 1.14 to 4 and were slightly negatively skewed with a mean of 2.41 out of 5 
and a SD of 0.77.  
Figure 4: Histogram of Intolerance of Uncertainty Average Scores 
 
Ambiguity Aversion 
The six item AA-MED scale was used to assess aversion to medical ambiguity. 
Higher scores indicate greater ambiguity aversion (possible range is 1-5). Ambiguity 
aversion scores ranged from 1.17 to 4.5, and were slightly positively skewed with a mean 
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of 2.72 out of 5 and a SD of 0.67. Ambiguity aversion and intolerance of uncertainty 
were moderately positively correlated (Pc=0.286 p=0.02). Thus, those who were less 
tolerant of uncertainty were more ambiguity averse. 
Figure 5: Histogram of Ambiguity Aversion Average Scores 
 
 
Optimism and Resilience 
Three items from the LOT-R were used to assess dispositional optimism, where 
higher scores represented more optimistic individuals (possible range is 1-5). The 10 item 
Connor-Davidson-Resilience Scale (CD-RISC) was used to measure resilience, where 
higher scores represented greater resilience (possible range is 0-40). Respondents were 
relatively optimistic with a mean of 3.63 out of 5 and a SD of 0.81 (range of 1.33 to 5) 
and resilient with a mean of 28.89 out of 40 and a SD of 5.47 (range of 12 to 40). 
Resilience was highly correlated with optimism (Pc=0.483 p<0.001) and moderately 
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correlated to intolerance for uncertainty (Pc=-0.311 p=0.014). Thus, those with greater 
resilience were more optimistic and less tolerant of uncertainty.  
 
Figure 6: Histograms of Optimism and Resilience Average Scores 
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Correlation of Personality Traits and Perceived Uncertainty 
Bivariate analysis was performed to determine the strength and significance of 
predicted relationships regarding personality traits and perceptions of uncertainty based 
on the proposed conceptual framework (Figure 1). There was little evidence to guide 
hypotheses about how personality traits would be related to participant’s perceptions of 
uncertainty. Therefore, we tested each trait against the overall perceived uncertainty as 
well as each domain of uncertainty measured by the PUGS. Overall perceptions of 
uncertainty were not correlated with intolerance of uncertainty, ambiguity aversion, 
optimism or resilience (Table 4). However, perceptions of evaluative uncertainty were 
correlated with ambiguity aversion (Pc=-0.34 p=0.006). Those who were more ambiguity 
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Perception of Genetic Health Care Provider’s Uncertainty 
Participants’ perceptions of their genetic health care providers’ uncertainty related 
to their genetic test result was assessed with the five items that make up the clinical and 
evaluative domains of the PUGS. Participants were prompted to rate their doctor or 
genetic counselors’ level of uncertainty or certainty about their result. Thus, mean scores 
were calculated for the two measured subscales. In general, respondents tended to 
perceive their genetic health care provider as having high certainty about their genetic 
test result. However, their perceptions of their GHP’s uncertainty were not statistically 
different than and they were highly correlated with their own perceptions (Table 5).  This 
suggests that participants in this study likely perceive themselves and their GHP as 
sharing similar levels of certainty about their test result.  
Table 5. Comparison of Perceptions of Personal and GHP Uncertainties (n=68) 
Domains Personal GHP 
t (p) Pc 
Mean (SD) Median  Mean (SD) Median 
Clinical 3.92 (1.06) 4.33  3.98 (1.01) 4.00 0.60 (0.55)  0.745**  
Affective 3.80 (1.12) 3.83  -- -- -- -- 
Evaluative 4.30 (0.81) 4.50  4.42 (0.74) 5.00  1.62 (0.11) 0.702** 
Total 3.97 (0.81) 4.06  -- -- -- -- 
** Correlation is significant at the 0.01 level (2-tailed) 
 
Recollections and Interpretations of Variant Pathogenicity, Cancer Risks, and 
Hereditary Likelihood 
The second aim of this study was to explore participants’ recollections, thoughts, 
and feelings about three pieces of information commonly communicated during cancer 
genetic counseling; variant pathogenicity, risk to develop cancer in the future, and 
likelihood that cancer is hereditary in their family. Frequencies were calculated for 
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variant pathogenicity variables and descriptive statistics were calculated for cancer risks 
and hereditary likelihood variables (Table 6).  
The six key outcome variables were discrepancies between client recall and 
interpretation (i.e. thoughts and feelings) of three aspects of genetic risk information. 
Differences were calculated by subtracting the recollected score from the corresponding 
thoughts or feelings score. Positive scores represented those whose interpretation was 
greater than their recollected score (e.g. those who felt their future cancer risk was greater 
than their recollected risk). Negative differences represented those whose interpretation 
was less than their recollected risk (e.g. those who felt they are less at risk to develop 
cancer than their recollected risk). A score of zero represented those individuals who 
interpreted their risk to be the same as their recollected risk. 
Table 6. Descriptive Statistics for Recollection, Thoughts, Feelings (n=60) 
 Recollection Thoughts Feelings 
Variant Pathogenicity (n, (%)) 















Cancer Risk (mean, (SD)) 3.90 (1.25) 4.32 (1.36) 4.48 (1.32) 
Hereditary Likelihood (mean, (SD)) 3.97 (1.79) 4.67 (1.74) 4.73 (1.73) 
 
Variant Pathogenicity  
Recollection 
Variant pathogenicity was measured on a 5-point scale that corresponded to the 
American College of Medical Genetics proposed variant classification categories. Thirty-
six participants (60%) recalled that their genetic health care provider had classified their 
variant as uncertain significance, 20 (33.3%) as benign or likely benign, and 4 (6.7%) as 
pathogenic.  
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Thoughts 
Thirty-two participants (53.3%) thought that their variant’s classification was 
uncertain significance, 19 (31.7%) that it was benign or likely benign, and 9 (15%) that it 
was likely pathogenic or pathogenic. Most participants (65%; n=39) thought their 
variant’s classification was the same as their recollection of what was communicated by 
their GHP. There was no difference in level of perceived uncertainty for those who 
thought differently about their test result compared to those who thought the same as their 
GHP (t=-0.75, df=58, p=0.45). 
Feelings 
Thirty participants (50%) felt that their variant’s classification was uncertain 
significance, 18 (30%) that it was benign or likely benign, and 12 (20%) that it was likely 
pathogenic or pathogenic. The majority of participants (56.7%; n=34) felt their variant’s 
classification was the same as their memory of what was communicated by their GHP. 
There was no difference in level of perceived uncertainty for those who felt differently 
about their test result compared to those who felt the same as their GHP (t=-1.55, df=58, 
p=0.13).  
Differences between recollection and interpretations 
Respondents’ recollection of their variant pathogenicity was subtracted from what 
they thought and what they felt their variant’s pathogenicity was to assess discrepancies 
in recall and interpretations.  Positive scores signified over-interpretation of their 
variant’s pathogenicity compared to their recollection while negative scores signified 
under-interpretation (possible range is -4 to 4).  Differences between thoughts and 
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recollection ranged from -2 to 2 and had a mean of 0.13  0.72 while differences between 
feelings and recollection ranged from -2 to 2 and had a mean of 0.17  0.81.  





Cancer Risk  
Recollection 
Cancer risk perception was measured on a 7-point scale from 1 (extremely 
unlikely) to 7 (extremely likely). Overall, respondents recalled intermediate cancer risks 
of 3.9 out of 7 and a SD of 1.25.  
Thoughts 
Participants thought they were at an elevated risk to develop cancer: 4.32 out of 7 
and a SD 1.36. Forty-eight participants (80%) reported that their genetic test result had 
influenced their thoughts about their risk to develop cancer, with 30% reporting that their 
perceptions were influenced very much or extremely by their result. Participants’ 
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uncertainty (Pc= -.127, p=0.33). However, perceptions of clinical uncertainty were 
correlated with their cognitive cancer risk perception (Pc=-0.27, p=0.04). Those who had 
less certainty (i.e. lower PUGS score) about how they would use their genetic test result 
clinically had higher cognitive cancer risk perceptions.  
Feelings 
Participants felt that they were at an elevated risk to develop cancer of 4.48 out of 
7 and a SD of 1.32. Forty-five participants (75%) reported that their genetic test result 
had influenced their feelings about their risk to develop cancer, with 30% reporting that 
their perceptions were influenced very much or extremely by their result. Participant’s 
feelings about their risk to develop cancer were not significantly correlated with their 
overall perceived uncertainty about their genetic test result (Pc= -.0.246, p=0.06). 
However, their clinical uncertainty perceptions were more strongly correlated with their 
affective cancer risk perceptions than their cognitive cancer risk perceptions. Those who 
had higher perceived clinical uncertainty (i.e. lower PUGS score) felt they were at higher 
risk to develop cancer in the future (Pc= -.0.361, p=0.005).   
Differences between recollection and interpretations 
To assess discrepancies in recall and interpretations, respondents’ recollection of 
their future cancer risk was subtracted from what they thought and what they felt their 
cancer risk was. Positive scores signified over-interpretation of their cancer risk 
perception compared to their recollection while negative scores signified under-
interpretation (possible range is -6 to 6).  Differences between thoughts and recollection 
ranged from -2 to 3 and had a mean of 0.42  1.03 while differences between feelings 
and recollection ranged from -2 to 3 and had a mean of 0.58  1.08. Most participants 
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(63.3% and 75%) thought and felt differently about their risk to develop cancer than what 
they recalled being communicated by their GHP. Moreover, participants thought and felt 
they were at a significantly higher risk to develop cancer in the future compared to their 
recollection (t=-3.13, p=0.003, df=59; t=-4.19, p<0.001, df=59).  





Hereditary Likelihood  
Recollection 
Perception of hereditary likelihood was measured on a 7-point scale from 1 
(extremely unlikely) to 7 (extremely likely). Overall respondents recalled intermediate 
hereditary likelihoods of 3.97 out of 7 and a SD of 1.79.  
Thoughts 
Participants thought that there was a high chance that cancer was heritable in their 
family with a mean of 4.67 and a SD of 1.74. Forty-four participants (73.3%) reported 
that their genetic test result had influenced their thoughts about the hereditary likelihood 
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extremely. Participants thoughts about the hereditary likelihood in their family were not 
correlated with their perceived uncertainty about their genetic test result.  
Feelings 
Participants felt there was a relatively high likelihood that cancer was hereditary 
in their family with a mean of 4.73 and a SD of 1.73. Forty-four participants (73.3%) 
reported that their genetic test result had influenced their feelings about the hereditary 
likelihood in their family, with 30% reporting that their perceptions were influenced very 
much or extremely. Participants’ feelings about the hereditary likelihood in their family 
were not correlated with their perceived uncertainty about their genetic test result. 
Differences between recollection and interpretations 
Participants’ recollection of the likelihood that cancer was hereditary in their 
family was subtracted from what they thought and what they felt was their family’s 
cancer hereditary likelihood. Positive scores signified over-interpretation of their cancer 
risk perception compared to their recollection while negative scores signified under-
interpretation (possible range is -6 to 6).  Differences between thoughts and recollection 
ranged from -1 to 4 and had a mean of 0.70  1.11 while differences between feelings 
and recollection ranged from -1 to 4 and had a mean of 0.77  1.14. Most participants 
(67.7% and 60%) reported thinking and feeling differently than their GHP about the 
chance that cancer was heritable in their family. Moreover, participants thought and felt a 
significantly higher chance that cancer was hereditary in their family compared to their 
recollected risk (t=-4.89, p<0.001, df=59; t=-5.207, p<0.001, df=59). 
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Figure 9: Histogram of Differences in Recollection and Interpretation Scores for 
Hereditary Likelihood  
 
 
Subjective Comprehension, Expectations, and Decisional Regret 
Respondents were relatively confident in their understanding of their genetic test 
result with a mean of 4.3 out of 5 and a SD of 0.67. Most participants (81.7%; n=49) 
reported that they knew of the possibility of an uncertain result prior to having genetic 
testing. Furthermore, respondents had relatively low regret about their decision to have 
genetic testing with a mean of 1.22 out of 5 and a SD of 0.61.   
Correlation of Key Variables as Framed by the Conceptual Model  
Using the conceptual model as a framework (Figure 1), bivariate analysis was 
performed to determine the strength of and significance of predicted relationships. We 
had little evidence to guide hypotheses about how perceived uncertainty would affect the 
key outcome variables. For this reason, perceived uncertainty was tested against each key 
outcome variable. Correlation analysis was used to determine which demographic and 
clinical characteristics were associated with key variables. Perceptions of uncertainty 
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recollection and interpretations (Figure 10).  







Correlation analysis found a significant negative relationship between perceptions 
of uncertainty and being non-Hispanic Caucasian such that those who were not Caucasian 
perceived greater certainty related to their variant result (Pc= -0.29 p=0.026). 
Furthermore, having children was found to be significantly negatively correlated with 
differences between recollection and thoughts of cancer risk such that those with children 
tended to under-interpret their risk to develop cancer compared to those without children 
(Pc = -0.321 p=0.014). No additional significant relationships were found among key 
variables and socio-demographic and other covariates measured in this study. Although 
this study is underpowered to detect correlations between key variables, those that are 
detected, are likely to persist following additional recruitment. With a larger sample size, 
we hope that further relationships between the key variables will be unveiled and can be 
tested in regression analyses.  
DISCUSSION 
Many clients who undergo testing for genetic cancer risk assessment (GCRA) 
receive variant of uncertain significance (VUS) result(s) that have no clinical utility. The 
purpose of this study was two-fold. First, this study sought to explore how individuals 
Perceived 
Uncertainty 
Think Pathogenicity-Recall Pathogenicity 
Feel Pathogenicity-Recall Pathogenicity 
Think Cancer Risk-Recall Cancer Risk 
Feel Cancer Risk-Recall Cancer Risk 
Think Hereditary -Recall Hereditary 
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who receive a VUS result in a cancer susceptibility gene perceive uncertainty related to 
their result. Additionally, this study sought to describe whether discrepancies between 
client recall and interpretation of genetic risk information are associated with their 
perceptions of uncertainty related to their VUS result. In the conceptual model (Figure 1), 
perceived uncertainty and personality traits are posited to contribute to meaning-based 
coping measured in this study as discrepancies between client’s recall and interpretations, 
including thoughts and feeling, of uncertain genetic risk information.  
Perceptions of Uncertainty 
A VUS result is an inherently uncertain result. However, despite this fact most 
participants in this study perceived high levels of certainty related to personal aspects of 
their VUS result. The high level of perceived certainty persisted across all domains and 
was highest for the evaluative domain suggesting participants tended to perceived the 
greatest certainty about the accuracy and trustworthiness of their test result. However, 
this high level of certainty may not be warranted as recent reports have shown that it is a 
common occurrence for variants to have conflicting interpretations between genetic 
testing laboratories; 11% of 518 variants in one recent study (Balmana et al. 2016). One 
participant cited such a conflict in interpretation of results. It is also somewhat surprising 
that participants perceived high levels of clinical certainty related to their result. By 
definition the relationship between a VUS and health risks are unknown, which is why 
the National Clinical Cancer Network (NCCN) guidelines recommend against utilizing 
VUS results during GCRA or when making individualized management 
recommendations.  Yet our findings suggest that clients perceive high certainty about 
how their results are related to their health, and how they and their doctor should use their 
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result to improve their health. This seems to suggest that clients may not appreciate how 
their GHP is (not) using their VUS result to inform their personalized risk assessment and 
management recommendations. Although in certain cases it may suggest that some health 
care providers are using VUS results to inform their risk counseling and management 
recommendations, which has been reported previously in studies of non-genetics health 
care providers (Plon et al., 2011, Cragun et al. 2016) and is supported by the one 
participant in this study that stated s/he had one doctor attribute meaning to their VUS 
result that had not been attributed by a GHP. Finally, participants reported high levels of 
certainty in the affective domain suggesting most felt certain about how they should 
emotionally respond to their result. This finding is interesting in the context of studies 
that have shown that some individuals receiving VUS results have greater psychological 
distress and worry compared to those receiving certain genetic test results (i.e. TN or PM) 
(van Dijk et al., 2006). Future studies could further elucidate how client’s perceptions of 
affective uncertainty may or may not be related to their distress after receiving an 
uncertain result. Finally, despite the overall high perceptions of certainty, a few 
participants highlighted additional uncertainties that were not assessed by the PUGS. 
These uncertainties echoed uncertainties described in prior studies of individuals 
receiving VUS results including uncertainties about the meaning of their result for their 
future cancer risks, their family members’ cancer risks, and when they should receive 
updated information about their variant or have additional genetic testing (Solomon et al. 
2013). Although these qualitative results cannot be generalized to individuals with VUS 
results, the fact that they were identified in two independent samples suggest that genetics 
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health care providers should be aware and attending to these as potential uncertainties 
that may arise when counseling individuals with VUS results.   
In this study personality traits were not related to overall perceptions of 
uncertainty as measured by the PUGS.  However, those who were more ambiguity averse 
had lower perceptions of certainty about the trustworthiness and accuracy of their result, 
which is a relationship consistent with prior studies (Biesecker et al., 2016). Non-
significance could suggest that these four personality traits do not contribute to how 
clients receiving a VUS result perceive personal uncertainties about their result. 
However, non-significance may also suggest that the small sample size and relative high 
ceiling for perceptions of certainty do not allow us to detect significant relationships. 
Studies with a larger sample population and greater diversity in perceptions of 
uncertainty would be better equipped to understand the actual relationships between 
personality traits and individual’s perceptions of uncertainty related to their VUS 
result(s).  
Another unique finding from this study was that clients perceived their genetic 
health care provider as having high certainty related to clinical and evaluative aspects of 
their genetic test result as well. This suggests that respondents perceived themselves as 
sharing what Han and colleagues describe as the ‘locus of uncertainty’; whether 
uncertainty exists in the minds of the clients, the provider, or both. It makes sense that 
clients would perceive themselves as sharing their perceptions of certainty with their 
provider as patients often model their perceptions of uncertainties in part on their 
interpretation of what their health care provider communicated, often someone regarded 
as a trusted expert. However, it is curious how clients rated their certainty regarding their 
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test result as essentially the same between themselves and their GHP, but then expressed 
markedly disparate perceptions of their variant pathogenicity and cancer risks when 
compared to their GHP. This suggests that there are likely other factors that play a role in 
the re-interpretation process of uncertain genetic risk information than solely their 
perceptions of uncertainty related to their genetic test result. Following additional 
recruitment of participants, it will be intriguing whether this finding stands.   
On the one hand, most participants in this study personally interpreted their result 
as being of uncertain significance while on the other they perceived few personal 
uncertainties about their result.  While these viewpoints seem contradictory, they support 
Vos and colleagues’ hypothesis that when faced with uncertain genetic test results 
individuals interpret the result with greater certainty as an adaptive way of coping with 
the uncertain information (Vos et al., 2008). In this way it is possible that participants 
perceived fewer personal uncertainties as a way of meaning based coping with the 
inherent uncertainty of their result. More research is needed to understand the 
consequences that may exist for clients perceiving a relatively high certainty about an 
uncertain genetic test result. However, if the goal of returning these results is to inform 
and educate clients about the uncertain nature of their result then data from this study 
suggests that message may be re-interpreted or lost in translation. Genetics health care 
providers have the opportunity during result disclosure to help clients explore their 
perceptions of certainty and/or uncertainty about their result, and help them to identify 
the potential consequences of holding these perceptions. Furthermore, they can use this 
exploration as a space to compare and contrast their own certainties and uncertainties 
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about their client’s result, which may lead to a more empathic and shared understanding 
about their variant result.   
Differences between recollection and interpretations  
Results from this study suggest that many if not most individuals receiving a VUS 
result in a cancer susceptibility gene re-interpret the meaning of their variants’ 
pathogenicity and their cancer risk perceptions as different from what they remember 
were communicated by their GHP. This is consistent with Vos and colleagues’ findings 
among clients with a VUS result and expands it to those receiving a VUS in cancer 
susceptibility genes other than BRCA1 and BRCA2. It is not novel, yet concerning, that 
some individuals in this study recalled that their GHP had classified their result as likely 
benign/benign or pathogenic. Moreover, half of participants felt that their variant was less 
or more pathogenic than what they recalled being communicated by their GHP, calling 
into question whether it is appropriate to return uncertain genetic test results to clients if a 
proportion will likely re-interpret their result’s pathogenicity as meaning more or less 
than what they remember being communicated. This is especially important to consider 
in the context of Vos’ research that suggested individual’s interpretations of their variant 
result are better predictors of their risk perceptions, familial communication practices, 
and behavioral outcomes than their actually communicated result. More research is 
needed to replicate Vos’ findings and strengthen the evidence for the consequences 
related to re-interpreting a VUS result as more or less pathogenic than their GHP.  
Participants in this study perceived significantly higher cancer risk perceptions 
and hereditary likelihoods than their recollections, suggesting there may be a sense of 
‘false alarm’ among this study population.  Clients’ tendency to over-interpret their 
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cancer risks and hereditary likelihood were not found to be related to their perceptions of 
uncertainty about their genetic test result, which may suggest that these perceptions are 
not associated with this phenomenon or that this study was not powered sufficiently to 
detect the actual relationship. We hypothesize that clients’ tendency to over-interpret risk 
information may be related to several factors. The first factor being some aspect of 
receiving a VUS result since most participants reported that their genetic test result 
influenced their risk perceptions with ~30% of participants reporting that their genetic 
result highly influenced their interpretations. Another may be related to Vos and 
colleagues’ hypothesis that clients reinterpret uncertain genetic information as having 
greater certainty as a way to cope with and manage their uncertainty. Although this seems 
discordant with the fact that most participants rated themselves as having high 
perceptions of certainty about their result, it is possible that the process of re-interpreting 
uncertain information as more certain occurs on a subconscious level that participants are 
unable to consciously report on. Furthermore, clients with a VUS may, and likely do, 
have a litany of other uncertainties (e.g. clinical, therapeutic, existential, etc.) that are 
more salient and play a larger role in the psychological process of re-interpretation of 
cancer risk information that were not measured in this study. Finally, we hypothesize that 
the tendency to re-interpret uncertain genetic information is influenced by factors related 
to GHP communication such as how much uncertainty is disclosed, how uncertainty is 
framed and how risks are presented.  
Unlike Vos’ studies, this study measured clients’ thoughts and feelings as separate 
and distinct from each other. While client’s thoughts and feelings were highly correlated 
in this study, participants’ thoughts and feelings were often different from each other and 
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their feelings tended to show greater valence towards under and over-interpretation of 
their variant result and cancer risk information when compared to their thoughts. These 
differences suggest that GHPs should explore clients’ thoughts and feelings about their 
VUS result and their cancer risk perceptions and can help normalize that their thoughts 
often are not the same as their feelings and the implications. Future research should 
investigate whether clients’ feeling at greater or less risk than what they remember being 
communicated by their GHP may be a better predictor of psychological and behavioral 
outcomes than traditional cognitive perceptions of risk.  
Clinical Implications 
Findings from this study have implications for cancer health care providers who 
work with individuals with a VUS in a cancer susceptibility gene. This study contributes 
to the understanding of how clients with VUS results perceive certainties and 
uncertainties related to their result and how they form subjective interpretations regarding 
their variant’s pathogenicity, cancer risks, and hereditary likelihoods. Data from this 
study suggests a disconnect exists between the inherent uncertainty of a VUS and 
individual’s personal perceptions of uncertainty about the result. It is up to GHPs to help 
their patients appreciate the personal uncertainties that surround their VUS result and 
how their genetic test result is or is not clinically utilized. This can be accomplished 
through pretest discussions about potential personal uncertainties associated with VUS 
results, explicit explanations about uncertainties during result disclosure, and through 
exploring clients’ perceived uncertainties about their result during and after disclosure. 
Furthermore, GHPs may make judgments of whether the potential harm of a client over-
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interpreting the meaning of their result is less than the potential benefits of disclosing the 
VUS information to their patient.  
In the context of disclosure, genetic health care providers such as genetic 
counselors can help clients make meaning of their results by engaging them in 
discussions about their personal thoughts and feelings regarding their result and their 
cancer risk perceptions. These conversations could then be leveraged as a means for 
GHPs to compare and contrast their own perspective with that of their clients. This is not 
to suggest that the ideal outcome would be for clients and GHPs to share the same 
perceptions. Rather GHPs could strive to help clients generate insight into how their 
thoughts and feelings may differ from their provider, and what the consequences of 
holding those perceptions are in their personal lives. In cases where clients’ 
interpretations are related to negative outcomes such as unwarranted prophylactic surgery 
or psychological distress, their GHP can suggest resources to help them manage their 
uncertainty such as mindfulness based stress reduction or cognitive behavioral 
interventions. Our results also suggest that clients would be interested in having a clear 
follow-up plan for receiving updated information about their VUS results and the state of 
the genetic testing science. Collaborating with patients to put a follow-up plan in place 
during the disclosure session could be an additional way to reduce uncertainty 
surrounding a VUS result.  
As indicated in the results, some socio-demographic variables were associated 
with perceptions of uncertainty and over-interpretation of cognitive cancer risk 
perceptions. This offers GHPs an opportunity to target interventions to those individuals 
who may be more susceptible to these tendencies.  For example, it may be even more 
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helpful to spend time discussing and exploring personal uncertainties about VUS results 
with non-Caucasian clients who were more likely to perceive greater certainty related to 
their result in this study.  
Study Limitations 
While the results from this study can be used to inform clinical cancer genetic 
counseling practice, there are several important limitations. As mentioned previously, the 
small sample size for this study may prevent finding significant relationships between 
key variables. In addition, the use of a cross-sectional study design limits our ability to 
make inferences about how relationships between key variables change over time.  
Other potential limitations may be related to the recruitment and the study 
population. Selection bias cannot be ruled out because it is possible that participants 
within the research registries that chose to participate may be different than those who 
chose not to participate. For instance, survey respondents may perceive higher certainty 
related to their genetic test result compared to non-respondents. The 16% response rate in 
this study was significantly lower than the 57% and 50% response rates reported in prior 
cross-sectional surveys among individuals enrolled in inherited cancer research registries 
(Culver et al., 2013; Vos et al., 2011). The lower response rate in this study may be 
attributed to several factors including; (1) participant concerns regarding privacy and 
confidentiality since this project was conducted by researchers at outside institutions (i.e. 
NIH and Johns Hopkins University); (2) additional burden since participants were 
required to review and provide a separate consent prior to completing the survey and; (3) 
the fact that prior studies did not stratify response rates by the registry participant’s type 
of genetic test result (e.g. benign, VUS, pathogenic). Due to these limitations, it is 
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difficult to assess how our response rate compares to prior studies among individuals 
with a VUS recruited through inherited cancer research registries.  Overall the study 
population was largely non-Hispanic Caucasian, female, married, and highly educated 
and therefore, may not be generalizable to the general U.S. population of individuals 
undergoing multi-gene panel testing for cancer susceptibility.  However, these 
characteristics have been associated with cancer genetic testing historically (Balmana et 
al., 2016).  
Finally, this study did not seek to compare differences between individual’s 
recollections and interpretations and the objective information actually communicated by 
their GHP. Both recollections and interpretations may be biased due to selective hearing 
by the participant and heuristic information processing. Moreover, genetic counseling 
practices may be significantly different at academic centers than at community cancer 
centers or in medical settings outside of oncology where cancer genetic testing is 
increasingly offered. Therefore, system and provider level factors that could contribute to 
the variance in patients’ recollections and interpretations of the genetic information 
outcomes may have been missed. Despite these limitations, this study was most interested 
in assessing interpretations of risk information because these are more deeply processed 
and connected with personal meaning. Identifying factors that influence how individuals 
reinterpret uncertain genetic information differently from their cognitive memory will be 
instrumental in developing interventions aimed at helping individuals make meaning of 
their uncertain genetic risk information rather than reducing their uncertainty. 
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Areas for future research 
 The purpose of this study was in part to examine the relationship between 
perceptions of uncertainty related to a variant result and discrepancies between recall and 
interpretations of uncertain genetic risk information. However, this study lacked the 
power to define these relationships at this time. Recruitment efforts will be continued to 
increase the sample size to allow for better interpretation of the relationships between key 
variables in this study. Future studies should include additional psychological and 
behavioral outcomes to better define what the consequences may be when an individual 
perceives him or herself and/or his or her families to be at greater risk for cancer as 
compared to their GHP. While this study was mainly interested in the client’s perceptions 
of uncertainty and risk information, future analysis could measure the actual 
communication process between GHPs and clients when discussing VUS results in order 
to better understand provider level factors that may contribute to key variables in this 
study. The PUGS scale offers the ability to compare perceptions of uncertainty related to 
VUS results in various clinical populations including those outside of the cancer setting. 
The scale can also be applied to GHPs to assess their levels of perceived uncertainty 
related to their client’s results, which can be contrasted to their clients’ perceptions post 
disclosure. Finally, longitudinal studies are needed to better understand temporal 
relationships among the key variables and to understand the dynamic process of 
perceptions of uncertainty and re-interpretation of uncertain genetic information.   
Conclusion 
This cross-sectional study of individuals with a VUS result in a cancer 
susceptibility gene identified that most perceive a relatively high level of certainty about 
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personal aspects of their result. This calls into question whether clients properly 
appreciate the inherent uncertainties related to their result. Further, this study highlights 
many clients with a VUS result consciously think and feel differently about their genetic 
risk information than their memory of what was communicated by their GHP. Regardless 
of what most clients recall their GHP communicating, clients perceived themselves and 
their families to be at greater risk for cancer and attributed their genetic test result as 
influencing their perceptions. Based on these results, GHPs should critically consider 
whether the potential benefits of returning a VUS result are greater than the potential 
harms that may occur when their clients subjectively re-interpret the meaning of their 
variant result. If GHPs continue to return VUS results, this study has clinical implications 
for what GHPs should be addressing when discussing VUS result(s) at the time of 
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Appendix A: Recruitment Letter 
 
[Participating Registry Logo] 
Dear Participant,  
 
You are being contacted because you are a part of the [Participating Hospital and 
Registry Title], which includes opportunities to be re-contacted for future research.  
You are invited to participate in a study conducted by researchers at the National 
Institutes of Health, Johns Hopkins University and [Participating Hospital]. The purpose 
of this study is to learn more about the experiences of people who have undergone cancer 
genetic counseling and testing, and to learn what people think and feel about their genetic 
test result. Ultimately, we hope this research will help improve the cancer genetic 
counseling and testing experience.  
The study involves filling out a survey, which we anticipate will take about 15 minutes to 
complete. The survey asks questions about your thoughts, feelings, and reactions to 
receiving your genetic test result. Individuals who join in this study will receive a $5 gift 
card as a token of our appreciation for your time.  
You may participate in this study if:  
1.You are 18 years or older 
2.You can read and write in English 
3.The interpretation of your genetic test result has not changed 
 
The survey can be found online at [consent form/survey link]. If you prefer to complete a 
paper version of the survey, please contact Devon Bonner at [phone number] or [email] 
to receive the survey and a pre-addressed and stamped return envelope. Your privacy is 
important to us. Any contact information you give to the researchers will not be linked to 
your survey responses. Furthermore, only the researchers at [Participating Hospital] will 
have access to your private health information.  
 
If you are willing to take part in this study, please read the information on the first page 
of the survey and check the box to show that you have read and voluntarily agreed to 
participate. If you agree to participate you will be asked to provide the authentication 
password listed below.   
 
Your password is [unique password].  
 
If you have any questions or concerns about this study please contact the researchers by 
phone or email. Thank you for your time and consideration. We look forward to learning 




[Researchers signature and contact information] 
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Appendix B: Consent Document 
 
INFORMED CONSENT FOR PARTICIPATION IN RESEARCH ACTIVITIES 
IRB #[IRB Number]: Understanding The Meaning Of Genetic Test Results For Cancer 
Susceptibility 
 
I. PURPOSE OF THIS RESEARCH STUDY: You have been asked to participate 
in this research study because you are a part of the [Registry Protocol Title], which 
includes opportunities to be re-contacted for future research. The purpose of this 
study is to learn more about the experiences of people who have undergone cancer 
genetic counseling and testing, and to learn what people think and feel about their 
genetic test result. This study involves a one-time survey that takes approximately 15 
minutes. 
 
About 240 people will take part in this study. 
 
II. WHAT WILL BE DONE: You will be invited to complete a survey: 
 The survey will ask you about your genetic counseling and testing experience 
and how you think and feel about your genetic test result. 
 Some of the questions will be multiple-choice while others will ask you to 
describe your thoughts and feelings in a few sentences.   
 The survey will take approximately 15 minutes. 
 
After completing the survey, you will be offered the opportunity to receive a $5.00 
gift card, in recognition of your completion of the survey.  If you agree to receive 
the $5 gift card, you will be asked to provide your name and contact address in a 
separate form that will not be linked to their survey responses or observed by the 
NIH researchers. Therefore, researchers at the NIH will not have access to 
identifiable information on survey respondents. The information you provide will 
only be used to send you the $5 gift card.  Your information will be destroyed once 
the gift card is mailed to you. 
 
If you want to remain anonymous, you should choose not to receive the $5 gift card 
or provide your information.  
 
Whether or not you choose to receive the $5 gift card and provide your name and 
address will not affect your ability to participate on this study or your ability to 
receive treatment at this institution in the future.  
 
If you choose to receive the $5 gift card and provide your name and address, the 
NIH researcher, Devon Bonner, will send you a $5 gift card. Your personal 
information will not be linked to your survey. We will not share your information 
with anyone outside the research team. The NIH researchers will analyze all study 
data anonymously and collectively. Your survey responses will not be placed in 
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your medical records. No reports from this study will include any information that 
could identify you. 
 
III. POSSIBLE BENEFITS:  You will not benefit from participation in this study. The 
information from this study may contribute to our understanding of cancer genetic 
testing and will be used to improve future patients’ cancer genetic counseling and 
testing experiences.   
 
IV. POSSIBLE RISKS: You may become tired from the amount of time needed to fill 
out the survey. It is possible that the content of the questions asked could upset you 
or make you uncomfortable. You can stop answering any questions at any time. If 
you feel upset by the survey you can contact the researchers listed below. You may 
also choose to contact your genetic counselor or doctor. 
 
V. ALTERNATIVES TO PARTICIPATION: Your alternative is to choose not to 
participate in this study.  Choosing not to participate will not interfere with any 
relationship with City of Hope. 
 
VI. CONFIDENTIALITY OF INFORMATION: Any information learned from this 
study in which you might be identified will be confidential and disclosed only with 
your permission. Every effort will be made to keep any information collected about 
you confidential. If you choose to receive the $5 gift card and provide your name 
and contact address, it is impossible to guarantee that information about you will not 
be mistakenly released.  If, despite our best efforts, identifying information about you 
is released, it could negatively impact you or your family members.  This risk is 
small.  
 
However, you allow the researchers to make your information available to 
Institutional Review Board (IRB) Office, the Cancer Protocol Review and 
Monitoring Committee (CPRMC), the Office for Human Research Protections 
(OHRP), the National Cancer Institute (NCI), and other regulatory agencies as 
required by law.   
 
VII. OFFER TO ANSWER QUESTIONS: If you have any further questions or 
concerns about this study, you can contact the principal investigator, [Collaborating 
PI] at [PI phone number] or the research genetic counselor, [Genetic counselor name 
and phone number]. You may also contact the NIH researcher, Devon Bonner, at 
[Phone number].  
 
VIII. SPONSOR OF THIS RESEARCH: The National Human Genome Research 
Institute Intramural Research Program at the National Institute of Health (NIH) is the 
sponsor of this research study.   
 
    63
IX. COST TO THE RESEARCH PARTICIPANT FOR PARTICIPATION: 
Neither you nor your insurance carrier will be charged for your participation in this 
study. 
 
X. FINANCIAL COMPENSATION: You will be offered a $5 gift card after 
completing the survey. You will be able to choose to receive your gift card by email 
or mail. Any contact information you provide will be destroyed after the gift card 
is sent. You are not required to receive a gift card to take part in the study. 
 
XI. VOLUNTARY PARTICIPATION WITH RIGHT OF REFUSAL: You have 
been informed that your participation in this research study is voluntary.  You are 
free to withdraw your consent for participation in this study without any loss of 
benefits, penalty, or interference with [Collaborating hospital].  
 
XII.  IRB REVIEW AND IMPARTIAL THIRD PARTY: This study has been 
reviewed and approved by the Institutional Review Board (IRB).  A representative 
of that Board, from the Office of Human Research Subjects Protection, is available 
to discuss the review process or your rights as a research subject.  The telephone 
number of the Office of Human Research Subjects Protection is (626) 256-HOPE 
(4673) ext. 62700. 
 
XIII.  AGREEMENT TO PARTICIPATION: By completing the survey you agree to 























    64
Appendix C: Survey Instrument 
 
Instructions: This survey should take you about 15 minutes to complete. Any responses 
you give will be anonymous and will not be linked to your private health information.  
The questions address your thoughts, feelings, and experiences with genetic testing. 
Some items are quite similar, but your thoughts and feelings may not always be the same. 
There are no right or wrong answers. 
 
Section A 
This section asks questions about your perceptions of uncertainty related to your genetic 
test result. There are no right or wrong answers.  
 
1.  In the table below, rate how uncertain or certain you are about the following 
















What my test results may mean for 
my health. 
     
What actions I need to take based 
on my test results. 
     
How my doctor may use my results 
to improve my health. 
     
Whether to be worried or 
concerned about my test results. 
     
Whether to be alarmed about my 
test results. 
     
Whether my test results will disrupt 
my life. 
     
Whether I can trust my test results.      
Whether my test results are 
accurate. 
     
 
2. Please describe anything else you are unsure about regarding your genetic test 
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3. In what ways do you see any positive aspects (good things) about any of the 





4. In what ways do you see any negative aspects (bad things) about any of the 






5. Generally, how are you feeling about the uncertainties related to your genetic test 






6.  We are also interested in your impressions of your genetic counselor or doctor’s 
uncertainty about your test results. Please rate how uncertain or certain you think 















What my test results may mean for 
my health. 
     
What actions I need to take based 
on my test results. 
     
How they may use my results to 
improve my health. 
     
Whether they can trust my test 
results. 
     
Whether my test results are 
accurate. 
     
 
Section B 
Moving on from your own thoughts and feelings, we are interested in what you 
remember talking about with your genetic counselor or doctor. Please do not worry about 
whether what you remember is correct.  
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7. How many variants (genetic changes) did your genetic counselor or doctor tell 
you were identified by your genetic test? ________ 
 
8.  If you learned of more than one variant, please think about the one that is most 
important or that you feel may mean the most for you. How did your genetic 
counselor or doctor classify this variant? Note that ‘benign’ means that a variant 
is present but the gene still works properly while ‘pathogenic’ means the variant 
is damaging (meaning the gene does not work properly). ‘Uncertain significance’ 
means that a variant is present but it is unknown whether the gene works properly 
or not.    
 







9.What is your risk to develop cancer in the future according to your genetic 















10. According to your genetic counselor or doctor what is the chance that cancer is 
















Please share your thoughts and feelings about your genetic test result, regardless of what 
any other person thinks or feels. There are no right or wrong answers.  
  
11. Please think about the same variant you kept in mind for the prior questions when 
completing the statements in the table below. Note that ‘benign’ means that a 
variant is present but the gene still works properly while ‘pathogenic’ means the 
variant is damaging (meaning the gene does not work properly). ‘Uncertain 
significance’ means that a variant is present but it is unknown whether the gene 











I think my variant is…      
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I think that 
my risk to 
develop 
cancer in the 
future is… 
       
I feel my risk 
to develop 
cancer in the 
future is… 
       









       









       
 
13. In this next table, please rate how much your genetic test result has influenced 













How much are your 
thoughts about your 
risk to develop 
cancer in the future 
influenced by your 
genetic test result? 
       
How much are your 
feelings about your 
risk to develop 
cancer in the future 
influenced by your 
genetic test result? 
       













How much are your 
thoughts about the 
chance that cancer is 
passed down from 
generation to 
generation in your 
family influenced by 
your genetic test 
result? 
       
How much are your 
feelings about the 
chance that cancer is 
passed down from 
generation to 
generation in your 
family influenced by 
your genetic test 
result? 
       
 








16. In what ways (if any) has your genetic test result changed your perception of 
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19. In what ways (if any) has your genetic test result influenced your perception of the 
chance that cancer is passed down from generation to generation in your family? 





Section D  
 
20. Please rate how well the following statements describe you. Rate each item on a scale 
from 1 (Not at all characteristic of me) to 5(Entirely characteristic of me).  
 
 Not at all 
characteristic 
of me 
Somewhat Unsure Very Entirely 
characteristic 
of me 
 1 2 3 4 5 
It really disturbs me when I 
am unable to follow another 
person’s train of thought. 
     
If I am uncertain about the 
responsibilities involved in a 
particular task, I get very 
anxious. 
     
Before an important task I 
must know how long it will 
take.  
     
I don’t like to work on a 
problem unless there is a 
possibility of getting a 
clear-cut and unambiguous 
answer. 
     
The best part of working on 
a jigsaw puzzle is putting in 
that last piece. 
     
I am often uncomfortable 
with people unless I feel that 
I can understand their 
behavior. 
     
A good task is one in which 
what is to be done and how 
it is to be done are always 
clear. 
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21. Please rate how strongly you agree with each statement as it describes you.  
 Strongly 
Disagree 
Disagree Neutral Agree 
Strongly 
Agree 
In uncertain times, I usually 
expect the best. 
     
It’s easy for me to relax.      
If something can go wrong for 
me, it will. 
     
I’m always optimistic about my 
future. 
     
I enjoy my friends a lot.      
It's important for me to keep busy.      
I hardly ever expect things to go 
my way. 
     
I don't get upset too easily.      
I rarely count on good things 
happening to me. 
     
Overall, I expect more good 
things to happen to me than bad. 
     
 






Disagree Neutral Agree 
Strongly 
Agree 
Conflicting expert opinions about 
a medical test or treatment would 
lower my trust in the experts. 
     
I would not have confidence in a 
medical test or treatment if experts 
had conflicting opinions about it. 
     
Conflicting expert opinions about 
a medical test or treatment would 
make me upset. 
     
I would not be afraid of trying a 
medical test or treatment even if 
experts had conflicting opinions 
about them.  
     
If experts had conflicting opinions 
about a medical test or treatment, I 
would still be willing to try it. 
     
I would avoid making a decision 
about a medical test or treatment if 
experts had conflicting opinions 
about it. 
     
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I am able to adapt to change.      
I can deal with whatever comes.      
I see the humorous side of things.      
Coping with stress makes me 
stronger. 
     
I tend to bounce back after illness, 
injury or hardship. 
     
I can achieve my goals.      
Under pressure, I focus and think 
clearly. 
     
I am not easily discouraged by 
failure. 
     
I think of myself as strong person.      









25. Before receiving your genetic test result, had you taken into account the 


















1 2 3 4 5 
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27. Please rate how strongly you agree or disagree with each statement about your 











It was the right decision      
I regret the choice that was 
made 
     
I would go for the same choice 
if I had to do it over again 
     
The choice did me a lot of 
harm 
     
The decision was a wise one      
 
28. Did you receive a letter or test report that summarized the information discussed 
when you received your genetic test result? 
 Yes If yes, continue to question 29 
 No 
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Appendix D: List of genes and associated cancers 
 
Gene Associated Neoplasia Citations 
APC Colon carcinoma 
Desmoid tumor 
Adrenal carcinoma 




Small intestine carcinoid 
Astrocytoma 
Osteoma 
OMIM: 175100, 135290 
NCCN guidelines: 
v.2.2016 






BRCA1 Breast Cancer 
Ovarian, Fallopian Tube, and Peritoneal 
Cancer 
Prostate Cancer 
OMIM: 604370, 614320  
NCCN guidelines: 
v.2.2016 
BRCA2 Breast Cancer 













BRIP1 Ovarian, Fallopian Tube, and Peritoneal 
Cancer 
Leukemia (bi) 
OMIM: 605882, 609054 
NCCN guidelines: 
v.2.2016 









CDH1 Lobular Breast Cancer 




DIS3L2 Wilms Tumors  OMIM: 614184 
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Renal Hamartomas (bi) 




Hepatobillary Tract Cancer 
Urinary Tract Cancer 









Medulloblastoma (bi)  












Hepatobillary Tract Cancer 
Urinary Tract Cancer 









Medulloblastoma (bi)  






















Medulloblastoma (bi)  









NBN Breast Cancer 





OMIM: 602667, 251260 
NCCN guidelines: 
v.2.2016 
NF1 Breast Cancer 
Optic glioma  
Malignant peripheral nerve sheath tumors 
Meningioma  
Hypothalamic tumor  
Neurofibrosarcoma  
Rhabdomyosarcoma  
Duodenal carcinoid  
Somatostatinoma  
Parathyroid adenoma  
Pheochromocytoma  
Pilocytic astrocytoma  
OMIM: 162200 
NCCN Guidelines: v 
2.2016 
PALB2 Breast Cancer 
Pancreatic Cancer 
Ovarian Cancer 




OMIM: 610355, 610832 
NCCN guidelines: 
v.2.2016 
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Medulloblastoma (bi)  




POLD1 Colorectal Cancer 
Uterine Cancer 
OMIM: 174761, 612591 
PTEN Breast Cancer 





Hamartomas or ganglioneuromas (GI) 
OMIM: 601728 
NCCN Guidelines: v 
2.2016 




RAD51C Ovarian Cancer OMIM: 602774 
NCCN Guidelines: v 
2.2016 
RAD51D Ovarian Cancer OMIM: 602954 




Gastrointestinal stromal tumors 
Renal cancer 
OMIM: 602413, 606764 
 
 









Sertoli cell testicular cancer 
Lung Cancer 
OMIM: 602216 
NCCN Guidelines: v 
2.2016 
SMAD4 Colorectal Cancer 
Gastric Cancer 
Small Intestine Cancer 
Pancreatic Cancer 
OMIM: 600993 
NCCN Guidelines: v 
2.2016 
TSC2 Renal carcinoma 
Neuroendocrine tumors 
Ependymoma  
Giant cell astrocytoma  
OMIM: 191092, 613254 
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Chordoma  
Benign tumors of the eye, heart, and lungs 
VHL Renal Cancer 
Pheochromocytomas 
Neuroendocrime Tumors of the Pancreas 
Hemangioblastoma 
Paraganglioma 
OMIM: 608537, 193300 
 
Bi= biallelic mutation carriers 
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